semaglutide .25 mg weight loss Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) UK approves first weight-loss tablet

Data demonstrates durable, lifestyle-first solutions for sustainable health outcomes Despite FDA prescription drug labeling recommendations to take GLP-1s in combination with diet and physical activity, before enrolling in the CVS Weight Management program, 70% of members were using a weight management drug without any lifestyle or nutrition support

(PDF) Mueller, E.M., Hofmann, S.G., Santesso, D.L., Meuret, A.E., Bitran, S., Pizzagalli, D.A

The most common reported effects were mild injection-site reactions and occasional headaches

Genetically susceptible follicles, particularly those at the crown and temples, possess higher concentrations of androgen receptors, making them more vulnerable to DHT-induced damage